埃夫加蒂格莫德是治疗三重阴性全般化肌痛严重症的有效治疗方法:三名患者的报告
相关实验视频
Updated: May 21, 2025
10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
12.3K
Jingyi Shen1, Chi Ma1, Ying Zhu1
1Department of Neurology, The First Affiliated Hospital of China Medical University, Shenyang, China.
Muscle & nerve
|May 20, 2025
概括
埃夫加蒂格莫德在治疗标准治疗不耐药的患者中,有望治疗三重阴性全般化肌痛性肌痛性肌痛性肌痛 (gMG). 这一案例系列表明efgartigimod可能是难以治疗的GMG病例的有效替代品.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 一般化肌痛性肌痛症 (gMG) 是一种影响神经肌肉结合的自身免疫性疾病.
- 乙胆受体抗体阳性 (AChR-Ab+) gMG是一种已知的亚型,但很大一部分gMG患者是三重阴性 (三重SN).
- 埃夫加蒂格莫德已被批准用于ACHR-Ab+gMG,但其在三重SNgMG中的有效性不太清楚.
研究的目的:
- 评估efgartigimod在三个被诊断为三重阴性全般化肌痛性肌痛症 (三重-SN gMG) 的患者中的治疗效果.
- 评估efgartigimod作为替代治疗选择的潜力,用于三重SN gMG对传统疗法无反应的患者.
主要方法:
- 对三名用efgartigimod治疗的三重SN gMG患者的医疗记录进行了回顾性审查.
- 埃夫加尔蒂基莫德每周10毫克/公斤,连续四周 (一个周期) 服用.
- 患者使用定量MG (QMG) 评分和MG日常生活活动 (MG-ADL) 尺度进行评估.
主要成果:
- 一名耐免疫抑制剂耐药的患者表现出改善,QMG和ADL得分减少.
- 2号患者对免疫球蛋白治疗反应不佳,在两次循环后实现了快速症状控制 (QMG:2;ADL:1).
- 3号患者经历了急性恶化,到第4周症状完全消失 (QMG:0,ADL:0).
结论:
- 初步证据表明,efgartigimod可能对三重SN gMG患者有效,这些患者对传统治疗反应不足.
- 这些发现突出了efgartigimod作为一种潜在的替代治疗选择.
- 进一步的多中心随机对照试验是有必要的,以确认在这个人群中有效性和安全性.
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
1.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.0K
01:15Myasthenia Gravis: Diagnostic Tests
581
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
581
01:20Antiepileptic Drugs: Potassium Channel Activators
138
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
138
01:28Disorders of the Skeletal Muscle
840
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
840
01:24Parkinson's Disease: Treatment
166
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
166
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
588
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
588